On December 27th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) – a type of targeted therapy known as a PARP inhibitor—for treatment of metastatic pancreatic cancer in people with a BRCA mutation.
This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.
On December 27th, the Food and Drug Administration (FDA) approved olaparib (Lynparza) – a type of targeted therapy known as a PARP inhibitor—for treatment of metastatic pancreatic cancer in people with a BRCA mutation.
by Teri Woodhull I am so excited for a new FORCE program called XRAY-Behind the Ovarian Cancer Headlines! My ovarian cancer was already advanced by the time it was diagnosed and I believe that research has played a big role in my nine-year survival. Admittedly, I’m a bit of a research junkie. I attend scientific … + read more
by Sue Friedman FORCE’s KNOW MORE campaign helps women diagnosed with ovarian, fallopian tube, or primary peritoneal cancers make informed decisions about genetic counseling and testing for inherited gene mutations. We launched a survey, which was completed by over 1,600 women with ovarian cancer. This blog continues our series on the survey results. We received over … + read more
by Lisa Rezende, PhD November is Pancreatic Cancer Awareness Month. FORCE wants to raise awareness of the risk of pancreatic cancer in the hereditary cancer community. Pancreatic cancer is rare but BRCA carriers have a high risk, up to 5% compared to the 1.5% for the general population. Between BRCA carriers, the risk is higher … + read more
By Heather Han, MD and Sue Friedman Metastatic Hereditary Breast Cancer Research There are major gaps in research, resources, and support for people with metastatic breast cancer – cancer that has spread beyond the breast and lymph nodes. A promising area of research is focusing on new treatments for hereditary metastatic breast cancer caused by … + read more
Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.
FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.
